Last mentioned: Mar 10, 2026
FY 2025 Earnings
Legend Biotech reports full-year financial results and 2026 strategic outlook.
Pipeline Update
Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
Manufacturing Milestone
Ghent facility reaches full operational capacity for commercial production.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
Label Expansion
Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.
FY 2025 Earnings
Legend Biotech reports full-year results and commercial highlights.
Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.